Mathew Thomas

3.6k total citations · 1 hit paper
28 papers, 2.2k citations indexed

About

Mathew Thomas is a scholar working on Immunology, Epidemiology and Rheumatology. According to data from OpenAlex, Mathew Thomas has authored 28 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Epidemiology and 6 papers in Rheumatology. Recurrent topics in Mathew Thomas's work include Systemic Lupus Erythematosus Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Mathew Thomas is often cited by papers focused on Systemic Lupus Erythematosus Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Mathew Thomas collaborates with scholars based in United States, India and Brazil. Mathew Thomas's co-authors include Z. John Zhong, William W. Freimuth, Lilia Pineda, A Gallacher, Roger A. Levy, Sandra Navarra, Stephen Hall, C Tănăsescu, Michelle Petri and Joung-Liang Lan and has published in prestigious journals such as The Lancet, Blood and Annals of the Rheumatic Diseases.

In The Last Decade

Mathew Thomas

26 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

2011 1.4k citations Sandra Navarra, Renato Guzmán et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mathew Thomas United States	12	1.5k	1.3k	850	188	188	28	2.2k
Meliha C Kapetanovic Sweden	28	1.7k 1.1×	1.0k 0.8×	370 0.4×	229 1.2×	436 2.3×	67	2.7k
Sandra Navarra Philippines	24	3.3k 2.2×	2.3k 1.8×	1.3k 1.5×	428 2.3×	220 1.2×	79	4.1k
Chan‐Bum Choi South Korea	24	1.0k 0.7×	420 0.3×	116 0.1×	178 0.9×	215 1.1×	79	1.6k
Francesca Bobbio‐Pallavicini Italy	25	1.0k 0.7×	357 0.3×	242 0.3×	194 1.0×	217 1.2×	39	1.7k
D. Adu United Kingdom	26	869 0.6×	534 0.4×	142 0.2×	139 0.7×	254 1.4×	58	2.9k
Frances Rees United Kingdom	12	1.0k 0.7×	499 0.4×	136 0.2×	230 1.2×	81 0.4×	19	1.6k
Colin Tang Hong Kong	18	1.1k 0.7×	375 0.3×	172 0.2×	179 1.0×	432 2.3×	29	2.1k
Carine Salliot France	21	1.5k 1.0×	453 0.4×	119 0.1×	313 1.7×	329 1.8×	63	2.5k
Olivier Fain France	30	689 0.5×	584 0.5×	115 0.1×	422 2.2×	247 1.3×	124	2.7k
Stephen P. McAdoo United Kingdom	27	474 0.3×	643 0.5×	102 0.1×	150 0.8×	142 0.8×	103	2.5k

Countries citing papers authored by Mathew Thomas

Since Specialization

Citations

This map shows the geographic impact of Mathew Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathew Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathew Thomas more than expected).

Fields of papers citing papers by Mathew Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathew Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathew Thomas. The network helps show where Mathew Thomas may publish in the future.

Co-authorship network of co-authors of Mathew Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Mathew Thomas. A scholar is included among the top collaborators of Mathew Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathew Thomas. Mathew Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sivina, Mariela, Nitin Jain, Ekaterina Kim, et al.. (2020). Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study. Blood. 136(Supplement 1). 22–23. 5 indexed citations

Lip, Henry Tan Chor, et al.. (2019). Predictors of mortality and validation of burn mortality prognostic scores in a Malaysian burns intensive care unit. BMC Emergency Medicine. 19(1). 66–66. 46 indexed citations

Burger, Jan A., Mariela Sivina, Alessandra Ferrajoli, et al.. (2017). Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 130. 427–427. 11 indexed citations

Thomas, Mathew, et al.. (2017). Metabolic acidosis in medical intensive care unit with indicators and their prognostic value- A prospective observational study. Asian Journal of Medical Sciences. 8(3). 60–67. 3 indexed citations

Kay, Jonathan, Arvind Chopra, S Chandrashekara, et al.. (2015). AB0420 Secondary Efficacy Outcomes from a Phase 3 Study Support Clinical Equivalence Between BOW015 and Infliximab in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. Annals of the Rheumatic Diseases. 74. 1034–1034. 5 indexed citations

Pitale, Shailesh, Mathew Thomas, Gaurav Rathi, et al.. (2014). A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis. Indian Journal of Endocrinology and Metabolism. 19(1). 148–148. 11 indexed citations

Kay, Jonathan, Arvind Chopra, S Chandrashekara, et al.. (2014). OP0012 A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. Annals of the Rheumatic Diseases. 73. 64–64. 14 indexed citations

Furie, R., Morton Scheinberg, G. Léon, et al.. (2013). OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE. Annals of the Rheumatic Diseases. 72. A90–A91. 4 indexed citations

Stohl, William, Falk Hiepe, Kevin Latinis, et al.. (2012). Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 64(7). 2328–2337. 311 indexed citations

10.

Glorioso, Nicola, Mathew Thomas, Chiara Troffa, et al.. (2012). Antihypertensive Efficacy and Tolerability of Aliskiren/Amlodipine Single- Pill Combinations in Patients with an Inadequate Response to Aliskiren Monotherapy¥. Current Vascular Pharmacology. 10(6). 748–755. 10 indexed citations

11.

Wallace, DJ, Sandra Navarra, M. Pétri, et al.. (2012). Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 22(2). 144–154. 88 indexed citations

12.

Navarra, Sandra, Renato Guzmán, A Gallacher, et al.. (2011). Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet. 377(9767). 721–731. 1401 indexed citations breakdown →

13.

Harding, Stephen, Helen J. Lachmann, JD Gillmore, et al.. (2010). Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis. Clinical Genetics. 84(2). 175–82. 2 indexed citations

14.

Gallacher, A, Roger A. Levy, Mathew Thomas, et al.. (2009). Late‐breaking abstracts: American College of Rheumatology 2009 Annual Scientific Meeting. Arthritis & Rheumatism. 60(12). 3859–3861. 4 indexed citations

15.

Thomas, Mathew. (2003). Medication Errors. Clinical Pediatrics. 42(4). 287–294. 1 indexed citations

16.

Pavithran, K, et al.. (2002). Chronic myeloid leukaemia in a man with myasthenia gravis treated by thymectomy. European Journal Of Haematology. 69(2). 105–107. 5 indexed citations

17.

Steele, Russell W., et al.. (2001). Compliance issues related to the selection of antibiotic suspensions for children. The Pediatric Infectious Disease Journal. 20(1). 1–5. 66 indexed citations

18.

Thomas, Mathew & Russell W. Steele. (1998). MONITORING SERUM VANCOMYCIN CONCENTRATIONS IN CHILDREN: IS IT NECESSARY?. The Pediatric Infectious Disease Journal. 17(4). 351–353. 9 indexed citations

19.

Steele, Russell W. & Mathew Thomas. (1998). Monitoring Serum Vancomycin Concentrations in Children: Is it Necessary? 914. Pediatric Research. 43. 158–158.

20.

Steele, Russell W., et al.. (1997). A Double-Blind Taste Comparison of Pediatric Antibiotic Suspensions. Clinical Pediatrics. 36(4). 193–199. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact